Portrait Published on 7 December 2016


Company : Valneva

Job : CEO

Year of creation : 1999

Atlanpole : Your Business in brief: Franck GRIMAUD :

Valneva is an independent company that specializes in the development, production and distribution of innovative vaccines.

The Group markets two vaccines against Japanese encephalitis (IXIARO®) and cholera (DUKORAL®), and has three vaccines under development (Pseudomonas aeruginosa, Clostridium difficile, Lyme disease). Valneva has also signed over 35 licensing agreements with leading global pharmaceutical companies (Sanofi, GlaxoSmithKline, Merial…) for the use of its innovative vaccine production platform, the EB66® cell line.

Valneva is listed on Euronext Paris and the Vienna Stock Exchange and operates from France, Austria, the UK, Sweden, the United States and Canada.

One of the few European biotechs which is close to being profitable.
A. : What about your connection with the Ecosystem network? F. G. :

With the support and assistance of Atlanpole from the outset, Valneva (initially Vivalis) started in 2000 with 3 employees in the premises of Nantes University Hospital. The Group has currently over 400  employees in 6 countries in Europe and North America!

The keys in Valneva’s development? In 2004, 5.3 million euros of funds were raised, notably from Pays de la Loire Développement, which allowed us to go over to industrial stage, an IPO in 2007 with the raising of EUR 29 million and a merger in 2013 with the Austrian company Intercell, not to mention the continuous support of the Grimaud group.

A. : Expected outcomes within 3 to 5 years? F. G. :

To become the world’s largest independent vaccines group by conjugating in-house growth and acquisitions.

Number of employees

Turnover trend

Back to Success stories